This course has expired. View available courses.
Nutrition
Probiotic Preventive Therapy: Reducing The Risks Of Antibiotic & C. difficile Associated Diarrhea – Mainpro+
Probiotic Therapy for Treatment of Antibiotic & C. difficile Associated Diarrhea
Antibiotics treat bacterial infections and save millions of lives but the use of antibiotics is also known to adversely influence the intestinal microbiota.1,2 The number of antibiotic scripts in Canada is significant, reaching millions every year. The potential impact on the health of patients who use them may be greater.2-4 A significant number of up to 39% of patients taking an antibiotic will experience antibiotic associated diarrhea (AAD), and possibly the more serious C. difficile associated diarrhea (CDAD) which has been shown to affect up to 20% of hospitalized adults.7,25,26
This program will examine the effect of antibiotics on the gut microbiota and the potential benefits of probiotic use.
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
1
ACCREDITATION
Mainpro+
EXPIRY DATE
2019-12-17
Probiotic Therapy for Treatment of Antibiotic & C. difficile Associated Diarrhea
Antibiotics treat bacterial infections and save millions of lives but the use of antibiotics is also known to adversely influence the intestinal microbiota.1,2 The number of antibiotic scripts in Canada is significant, reaching millions every year. The potential impact on the health of patients who use them may be greater.2-4 A significant number of up to 39% of patients taking an antibiotic will experience antibiotic associated diarrhea (AAD), and possibly the more serious C. difficile associated diarrhea (CDAD) which has been shown to affect up to 20% of hospitalized adults.7,25,26
This program will examine the effect of antibiotics on the gut microbiota and the potential benefits of probiotic use.
Faculty
Deanna Telner (MD, CCFP)
Dragana Skokovic-Sunjic (BScPhm, RPh, NCMP)
John Axler (MD, CCFP, FCFP)
Lydia Hatcher (MD, CCFP, FCFP, CHE, CAPM)
Learning objectives
On completion of this program, participants will be better able to:
- Review current recommendations for treatment intensification for people with type 2 diabetes (T2D) who require treatment intensification beyond oral agents
- Assess when injectable therapy should be considered and appreciate the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in T2D management
- Recall the indication, safety and efficacy of GLP-1RAs
- Differentiate between GLP-1RA options available in Australia